CompletedPhase 2NCT04849351
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hutchison Medipharma Limited
- Principal Investigator
- junning Cao, Ph.DFudan University
- Intervention
- HMPL-689(drug)
- Enrollment
- 178 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (30)
- The Second Hospital of Anhui Medical University, Hefei, Anhui, China
- Beijing Chao-yang Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Beijing GoBroad Boren Hospital, Beijing, Beijing Municipality, China
- Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
- Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
- The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
- Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
- Hainan General Hospital, Haikou, Hainan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04849351 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLThe First Affiliated Hospital with Nanjing Medical University